Sequential BV‐AVD Therapy in Richter Transformation: Insights Into the Management of Elderly Patients
Hematological Oncology · 2026-05 · 44 (3)
DOI: 10.1002/hon.70197 ↗At a glance
Fallbericht in Hematological Oncology, published online on 2026-05-13. Written by Arianna Bevilacqua and 10 co-authors. Institution: Hematology Unit, Department of Medicine, University of Padova, Padua, Italy. Major MEDLINE topics: Antineoplastic Combined Chemotherapy Protocols, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell. Cited 1 times so far (Crossref); 11 references. Funded by: Associazione Italiana per la Ricerca sul Cancro, Progetti di Rilevanza Nazionale PRIN PNRR, Ricerca per Credere nella Vita odv.
Abstract (original language)
Hodgkin‐variant Richter's transformation (HvRT) is a rare evolution of chronic lymphocytic leukemia (CLL) into a lymphoma with histological characteristics akin to those of classical Hodgkin lymphoma (cHL), overall occurring in < 1% of CLL cases. Due to its rarity, treatment is not standardized and is commonly adapted from cHL regimens, although toxicity limits their use in older or heavily pretreated patients. We describe two cases of HvRT treated with a modified sequential brentuximab vedotin‐AVD‐brentuximab vedotin (BV‐AVD‐BV) regimen, previously explored in elderly patients with cHL. Sequential BV‐AVD‐BV was feasible and manageable in both cases, with acceptable hematologic toxicity. One patient achieved a durable complete metabolic remission, while the other required immune checkpoint inhibitor‐based salvage therapy followed by autologous stem cell transplantation, resulting in complete metabolic response. These cases suggest that sequential BV‐AVD‐BV may represent a tolerable and effective therapeutic option for selected patients with HvRT. Incorporation of modern Hodgkin‐directed strategies, including sequential regimens and immune checkpoint inhibitors, warrants further evaluation in this rare clinical setting.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Hematology Unit, Department of Medicine, University of Padova, Padua, Italy.
- Surgical Pathology and Cytopathology Unit, Department of Medicine, University of Padova, Padua, Italy.
ORCID profiles: Giovanni Leone, Francesco Piazza
Funding
- Associazione Italiana per la Ricerca sul Cancro
- Progetti di Rilevanza Nazionale PRIN PNRR
- Ricerca per Credere nella Vita odv
- Supporting Talent in ReSearch@University of Padua
Cite
APA
Bevilacqua, A., Cellini, A., Danesin, N., Angotzi, F., Serafin, A., Leone, G., D'Antiga, M., Piazza, F., Pizzi, M., Trentin, L., & Visentin, A. (2026). Sequential BV‐AVD Therapy in Richter Transformation: Insights Into the Management of Elderly Patients. Hematological Oncology, 44(3). https://doi.org/10.1002/hon.70197
Vancouver
Bevilacqua A, Cellini A, Danesin N, Angotzi F, Serafin A, Leone G, et al. Sequential BV‐AVD Therapy in Richter Transformation: Insights Into the Management of Elderly Patients. Hematological Oncology. 2026;44(3). doi:10.1002/hon.70197
BibTeX
@article{Bevilacqua2026,
author = {Bevilacqua, Arianna and Cellini, Alessandro and Danesin, Nicolò and Angotzi, Francesco and Serafin, Andrea and Leone, Giovanni and D'Antiga, Mattia and Piazza, Francesco and Pizzi, Marco and Trentin, Livio and Visentin, Andrea},
title = {Sequential BV‐AVD Therapy in Richter Transformation: Insights Into the Management of Elderly Patients},
journal = {Hematological Oncology},
year = {2026},
volume = {44},
number = {3},
doi = {10.1002/hon.70197}
}
EUVIMED